Involvement of the receptor for advanced glycation-end products (RAGE) in β-amyloid-induced toxic effects in rat cerebromicrovascular endothelial cells cultured in vitro

International Journal of Molecular Medicine

Volumn 24, Issue 1, 2009, Pages 9-15

  Baiguera, Silvia ^a   Fioravanzo, Lara ^a   Grandi, Claudio ^a   Di Liddo, Rosa ^a   Parnigotto, Pier Paolo ^a   Folin, Marcella ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

amyloid; Cerebromicrovascular endothelial cells; Nitrergic system; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTIBODY; AMYLOID BETA PROTEIN[1-42]; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL CELL CULTURE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN BLOOD VESSEL; CELL FUNCTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MICROVASCULATURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; RECEPTOR BINDING;

AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GLYCOSYLATION END PRODUCTS, ADVANCED; MALE; MICROVESSELS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC;

EID: 67649562150     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000199     Document Type: Article

References (40)

1. Farkas E and Luiten PGM: Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 64: 575-611, 2001.
2. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, Duff K, Dickson D and Van Broeckhoven C: Dense core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 167: 527-543, 2005.
3. Van Broeck B, Van Broeckhoven C and Kumar-Singh S: Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches. Neurodegener Dis 4: 349-365, 2007.
4. Humpel C and Marksteiner J: Cerebrovascular damage as a cause for Alzheimer's disease. Curr Neurovasc Res 2: 341-347, 2005.
5. Deane R and Zlokovic BV: Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4: 191-197, 2007.
6. Zlokovic BV: Clearing amyloid through the blood-brain barrier. J Neurochem 89: 807-811, 2004.
7. Begley DJ and Brightman MW: Structural and functional aspects of the blood-brain barrier. Prog Drug Res 61: 39-78, 2003.
8. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF and Yan SD: RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 7: 735-742, 2007.
9. Lue LF, Yan SD, Stern DM and Walker DG: Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 4: 249-266, 2005.
10. Munoz FJ, Opazo C, Gil-Gomez G, Tapia G, Fernandez V, Valverde MA and Inestrosa NC: Vitamin E but not 17beta-estradiol protects against vascular toxicity induced by beta-amyloid wild type and the Dutch amyloid variant. J Neurosci 22: 3081-3089, 2002.
11. Folin M, Baiguera S, Fioravanzo L, Conconi MT, Grandi C, Nussdorfer GG and Parnigotto PP: Caspase-8 activation and oxidative stress are involved in the cytotoxic effect of β-amyloid on rat brain microvascular endothelial cells. Int J Mol Med 17: 431-435, 2006.
12. Neuroinflammation Working Group: Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421, 2000.
13. Smith MA, Richey Harris PL, Sayre LM, Beckman JS and Perry G: Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17: 2653-2657, 1997.
14. Luth HJ, Holzer M, Gartner U, Staufenbiel M and Arendt T: Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res 913: 57-67, 2001.
15. Luth HJ, Munch G and Arendt T: Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res 953: 135-143, 2002.
16. Verdier Y, Zarándi M and Penke B: Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J Pept Sci 10: 229-248, 2004.
17. Ramírez G, Rey S and von Bernhardi R: Proinflammatory stimuli are needed for induction of microglial cell-mediated AbetaPP{244-C} and Abeta-neurotoxicity in hippocampal cultures. J Alzheimers Dis 15: 45-59, 2008.
18. Akama KT, Albanese C, Pestell RG and Van Eldik LJ: Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc Natl Acad Sci USA 95: 5795-5800, 1998.
19. Koh SH, Kim SH, Kwon H, Park Y, Kim KS, Song CW, Kim J, Kim MH, Yu HJ, Henkel JS and Jung HK: Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. Brain Res Mol Brain Res 118: 72-81, 2003.
20. Folin M, Baiguera S, Tommasini M, Guidolin D, Conconi MT, De Carlo E, Nussdorfer GG and Parnigotto PP: Effects of β-amyloid on rat neuromicrovascular endothelial cells cultured in vitro. Int J Mol Med 15: 929-935, 2005.
21. Abbot NJ, Hughes CCW, Revest PA and Greenwood J: Development and characterization of rat brain capillary endothelial culture: towards an in vitro blood-brain barrier. J Cell Sci 103: 23-27, 1992.
22. Conconi MT, Lora S, Baiguera S, Boscolo E, Folin M, Scienza R, Rebuffat P, Parnigotto PP and Nussdorfer GG: In vitro culture of rat neuromicrovascular endothelial cells on polymeric scaffolds. J Biomed Mat Res 71: 669-674, 2004.
23. Baiguera S, Conconi MT, Guidolin D, Mazzocchi G, Malendowicz LK, Parnigotto PP, Nussdorfer GG and Ribatti D: Ghrelin inhibits in vitro angiogenic activity of rat brain microvascular endothelial cells. Int J Mol Med 14: 849-854, 2004.
24. Guidolin D, Vacca A, Nussdorfer GG and Ribatti D: A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. Microvasc Res 67: 117-124, 2004.
25. Suo Z, Fang C, Crawford F and Mullan M. Superoxide free radical and intracellular calcium mediate Aβ(1-42) induced endothelial toxicity. Brain Res 762: 144-152, 1997.
26. Thomas T, McLendon C, Sutton ET and Thomas G: Cerebrovascular endothelial dysfunction mediated by beta-amyloid. Neuroreport 8: 1387-1391, 1997.
27. Poduslo JF, Curran GL, Sanyal B and Selkoe DJ: Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol Dis 6: 190-199, 1999.
28. Donahue JE, Flaherty SL, Johanson CE, Duncan JA III, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V and Stopa EG: RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112: 405-415, 2006.
29. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D and Kindy M: Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6: 643-651, 2000.
30. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM and Yan SD: Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 171: 29-45, 2001.
31. Schmidt AM, Yan SD, Yan SF and Stern DM: The biology of the receptor for advanced glycation and products and its ligands. Biochim Biophys Acta 1498: 99-111, 2000.
32. Bateman DA, McLaurin J and Chakrabartty A: Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding. BMC Neurosci 8: 29-41, 2007.
33. Law A, Gauthier S and Quirion R: Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type. Brain Res Brain Res Rev 35: 73-96, 2001.
34. Goodwin JL, Kehrli ME Jr and Uemura E: Integrin Mac-1 and beta-amyloid in microglial release of nitric oxide. Brain Res 768: 279-286, 1997.
35. Wallace MN, Geddes JG, Farquhar DA and Masson MR: Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques. Exp Neurol 144: 266-272, 1997.
36. Dorheim MA, Tracey WR, Pollock JS and Grammas P: Nitric oxide synthase activity is elevated in brain microvessels in Alzheimer's disease. Biochem Biophys Res Commun 205: 659-665, 1997.
37. Rojas A, Caveda L, Romay C, López E, Valdés S, Padrón J, Glaría L, Martínez O and Delgado R: Effect of advanced glycosylation end products on the induction of nitric oxide synthase in murine macrophages. Biochem Biophys Res Commun 225: 358-362, 1996.
38. Amore A, Cirina P, Mitola S, Peruzzi L, Gianoglio B, Rabbone I, Sacchetti C, Cerutti F, Grillo C and Coppo R: Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells. Kidney Int 51: 27-35, 1997.
39. Sumi D and Ignarro LJ: Regulation of inducible nitric oxide synthase expression in advanced glycation end product-stimulated raw 264.7 cells: the role of heme oxygenase-1 and endogenous nitric oxide. Diabetes 53: 1841-1850, 2004.
40. Chang P-C, Chen T-H, Chang C-J, Hou C-C, Chan P and Lee H-M: Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney Int 65: 1664-1675, 2004.